X
[{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$225.5 million","upfrontCash":"$10.0 million","newsHeadline":"Affibody and Inmagene Announce Strategic Partnership to Develop ABY-035","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affibody Announces Initiation of Confirmatory Phase 2 Trial of ABY-035 in Psoriatic Arthritis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene and Affibody Announce IND Clearance for Izokibep (IMG-020) For the Treatment of Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Affibody","sponsor":"Acelyrin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Affibody","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$214.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affibody And Chiesi Group Collaborate To Develop And Commercialize Innovative Treatments For Respiratory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Affibody
Filters
Companies By Therapeutic Area
Details:
Under the terms of the collaboration, Affibody and Chiesi Group will collaborate closely to progress up to three programs based on Affibody® molecules against undisclosed targets for respiratory diseases.
Lead Product(s):
Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Chiesi Group
Deal Size: $214.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
March 07, 2023
Details:
IMG-020 (Izokibep), a unique, antibody mimetic, interleukin-17A (IL-17A) inhibitor was well-tolerated in the study, having a favorable safety profile consistent with that previously observed for izokibep and the IL-17A inhibitor therapeutic class.
Lead Product(s):
Izokibep
Therapeutic Area: Immunology
Product Name: IMG-020
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Recipient:
Acelyrin
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 03, 2022
Details:
IMG-020, Inmagene's most advanced drug candidate, is in global clinical trials for multiple indications. The trial will evaluate the efficacy, safety and tolerability of three different dosage regimens of izokibep as compared to placebo.
Lead Product(s):
Izokibep
Therapeutic Area: Immunology
Product Name: IMG-020
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Recipient:
Inmagene Biopharmaceuticals
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 10, 2021
Details:
The study is a multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial in patients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035.
Lead Product(s):
ABY-035
Therapeutic Area: Immunology
Product Name: ABY-035
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 10, 2020
Details:
The Phase 2 AFFIRM-35 trial in patients with moderate-to-severe psoriasis has shown excellent and sustained clinical response in patients. Based on these encouraging clinical results, clinical development program of ABY-035 has been expanded to include further indications.
Lead Product(s):
ABY-035
Therapeutic Area: Dermatology
Product Name: ABY-035
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 16, 2020
Details:
The parties will develop and commercialize ABY-035 for multiple auto-immune diseases. Inmagene will Commercialize ABY-035 in mainland China, Hong Kong, Taiwan, and Macau, and South Korea, and will run developmental activities in the Asia Pacific region.
Lead Product(s):
ABY-035
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Inmagene Biopharmaceuticals
Deal Size: $225.5 million
Upfront Cash: $10.0 million
Deal Type: Partnership
May 15, 2020